Dubai, United Arab Emirates – Healthcare companies in Ireland are ready to meet the fast growing demand from healthcare providers in the UAE and wider region for world class healthcare expertise and innovative cutting edge solutions. In the UAE alone, market analysis estimates that healthcare spending is set to reach $2.4 billion by 2025, and $3.6 billion by 2030.

With Arab Health 2020 being the largest healthcare exhibition and conference in the MENA region starting this week, Ireland will be fielding a strong group of highly innovative healthcare companies showcasing the latest in world class healthcare expertise and solutions on its pavilion looking to expand their export footprint across the region which has become a key priority market.

In the medical technologies – or medtech as its more commonly referred to – sector alone, Ireland has established its strong reputation as a leading global player with 9 of the world’s top 10 medtech companies based there. It is a vitally important sector to the Irish economy that generates annual exports valued at €12.6 billion EUROS ($13.9 billion), supporting over 40,000 jobs across the 450 medtech companies in the country.

Commenting on the global and regional medtech opportunity for Ireland, Eamon Sikafi, Senior Market Advisor for the Middle East & North Africa at Enterprise Ireland, the Irish State agency that works with Irish enterprises to help them start, grow, innovate and win export sales in global markets said, “Irelands medtech companies have their sights set on increasing their share of the global market for medtech which is estimated to be worth €530 billion EUROS by 2024. The medtech industry in Ireland exports to over 100 countries worldwide and is recognised as among the leading global innovative suppliers of cutting edge healthcare solutions in the market”.

“In the middle east region, the demand for medtech is forecasted to be worth $31.6 billion by 2025, which is why Enterprise Ireland backed companies view Arab Health 2020 as the key platform to forge ever closer links to the local healthcare providers and showcase their world leading medtech solutions to the region”.

Two out of the 14 Irish companies hosted by Enterprise Ireland on the Ireland pavilion have already finalised a number of commercial deals which be formally announced at Arab Health this week, with more set to be agreed in the coming days.

Irish family owned business, Fleming Medical is a leading innovator of diagnostic, sports therapy, first aid and wound care products operating in more than 20 countries, will announce three commercial deals valued at over $2.43 million. These will include:

  • Awarded the private label contract for Saudi Arabia’s second largest pharmacy chain, Al- dawaa Pharmacy, to provide their sport therapy product range which is set to be worth over $1 million over the next three years.
  • Three year agreement with Bahrain’s retail pharmacy chain and distribution company, Hamad Medical, which is worth around $800,000.
  • New three year contract worth at least $630,000 with Qatar based distribution company, Khalid Scientific, for the supply of several of Fleming Medical’s medical devices.

Highlighting these successful commercial deals announced at Arab Health 2020, Fleming Medical’s Managing Director, Mark Fleming said, “We are delighted to continue our expansion across the Middle East, which represents an important market opportunity for us. This news further strengthens both the Fleming Medical, Medicare and Physiologix brands on the international stage.”

Digital Health company myPatientSpace will be making two formal announcements at Arab Health 2020. A provider of an innovative collaborative patient engagement platform, myPatientSpace will announce agreements with Neuro Spinal Hospital and Manzil Healthcare Services.

  • Manzil Healthcare Services, the region’s leading Disease Management and Digital Health Services provider, is partnering with myPatientSpace to enhance its Disease Management and Patient Support Programs with next-generation Digital Patient Engagement
  • The Neuro Spinal Hospital, Dubai, the renowned centre of excellence for neurosciences, will be the first hospital to launch with myPatientSpace in the region, and - along with opening its new hospital, will offer a personalised digital health companion to support and connect with patients throughout their treatment journey.

Commenting on the UAE agreements with Manzil Healthcare Services and the Neuro Spinal Hospital, myPatientSpace CEO and Founder, Una Kearns said, “We are incredibly excited to expand our platform to the Middle East, working with Neuro Spinal Hospital and Manzil Healthcare Services to bring our Digital Health Companion to their patients, improving outcomes, driving care efficiency, and gathering real world evidence. Improving patient experience and patient health is at the core of our shared mission and we look forward to our collaboration.”

Neuro Spinal Hospital’s Chief Operating Officer, Dana Msaddi, said, “This agreement with myPatientSpace will strengthen Dubai’s credentials as a healthcare hub in the Middle East and raise the bar on patient experience to global standards.”

With further commercial agreements expected to be finalised this week at Arab Health 2020, Enterprise Ireland will host the Ireland pavilion located at H2, A10 for 14 Irish companies that will include digital health companies: Medentech/Kersia-Group; myPatientSpace; Empeal; MEG Support Tools; GetReferd; and, Tapa Healthcare. Medtech companies: Aerogen; Novaerus; Theya Healthcare; Profilo-Smart; and, Maria Medical Technology. Pharmaceutical companies: Precision Biotics; CF Pharma; and, Fleming Medical.

© Press Release 2020

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.